共存慢性淋巴细胞性甲状腺炎对低中危甲状腺乳头状癌中央区淋巴结转移的临床影响:MASTER研究
MASTER研究回顾了2020年6月至2022年3月接受肺叶切除和中央区颈淋巴结清扫的1,022例低中危甲状腺乳头状癌患者,其中102例(10.0%)共存慢性淋巴细胞性甲状腺炎。多因素分析显示年轻、男性、肿瘤>1cm、甲状腺外侵犯和脉管侵犯是中央区淋巴结转移的危险因素,脉管侵犯是共存慢性淋巴细胞性甲状腺炎患者中央区淋巴结转移的唯一独立危险因素。作者认为共存慢性淋巴细胞性甲状腺炎可能被视为对抗中央区淋巴结转移的潜在因素。
要点
- 1,022例低中危甲状腺乳头状癌患者中,102例(10.0%)共存慢性淋巴细胞性甲状腺炎。
- 共存慢性淋巴细胞性甲状腺炎患者中,女性、多灶肿瘤和脉管侵犯是独立相关因素。
- 脉管侵犯是共存慢性淋巴细胞性甲状腺炎患者中央区淋巴结转移的唯一独立危险因素。
核心结论
- 作者认为,低中危甲状腺乳头状癌共存慢性淋巴细胞性甲状腺炎患者表现出与无慢性淋巴细胞性甲状腺炎患者不同的临床特征。
- 作者认为,共存慢性淋巴细胞性甲状腺炎可能被视为对抗中央区淋巴结转移的潜在因素。
研究设计与样本
- 回顾性分析2020年6月至2022年3月接受肺叶切除和中央区颈淋巴结清扫的1,022例低中危甲状腺乳头状癌患者的病历资料。
- 比较有无共存慢性淋巴细胞性甲状腺炎患者的临床病理因素差异,并评估中央区淋巴结转移的危险因素。
主要发现
- 1,022例患者中,102例(10.0%)共存慢性淋巴细胞性甲状腺炎;358例(35%)发生中央区淋巴结转移。
- 与无慢性淋巴细胞性甲状腺炎患者相比,共存慢性淋巴细胞性甲状腺炎患者中女性(OR=3.536,P=.001,95%CI 1.781-8.069)、多灶肿瘤(OR=2.162,P=.001,95%CI 1.358-3.395)和脉管侵犯(OR=0.365,P<.001,95%CI 0.203-0.625)是独立相关因素。
- 多因素分析显示,中央区淋巴结转移的危险因素包括年轻年龄(OR=0.667,P=.013,95%CI 0.482-0.555)、男性(OR=0.549,P<.001,95%CI 0.402-0.751)、肿瘤大小>1cm(OR=1.454,P=.022,95%CI 1.053-2.003)、甲状腺外侵犯(OR=1.874,P<.001,95%CI 1.414-2.486)和脉管侵犯(OR=3.094,P<.001,95%CI 2.339-4.101)。
- 在共存慢性淋巴细胞性甲状腺炎患者中,脉管侵犯(OR=11.184,P<.001,95%CI 3.277-46.199)是中央区淋巴结转移的唯一独立危险因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinicopathological impact of chronic lymphocytic thyroiditis on patients with papillary thyroid carcinoma patients is still controversial. This study aimed to evaluate the clinicopathologic differences and risk factors for central lymph node metastasis based on the presence of coexistent chronic lymphocytic thyroiditis in patients with low- to intermediate-risk papillary thyroid carcinoma. METHODS: The medical records of 1,022 patients with low- to intermediate-risk papillary thyroid carcinoma who underwent lobectomy and central neck dissection between June 2020 and March 2022 were reviewed. Differences in clinicopathological factors were analyzed in patients with papillary thyroid carcinoma with or without chronic lymphocytic thyroiditis. Furthermore, risk factors for central lymph node metastasis in patients with low- to intermediate-risk papillary thyroid carcinoma with or without chronic lymphocytic thyroiditis were evaluated. RESULTS: Among the 1,022 patients with low to intermediate-risk papillary thyroid carcinoma, 102 (10.0%) had coexisting chronic lymphocytic thyroiditis. Female sex (odds ratio = 3.536, P = .001, 95% confidence interval 1.781-8.069), a multifocal tumor (odds ratio = 2.162, P = .001, 95% confidence interval 1.358-3.395), and angiolymphatic invasion (odds ratio = 0.365, P < .001, 95% confidence interval 0.203-0.625) were independent factors associated with patients who had coexisting chronic lymphocytic thyroiditis compared to those without chronic lymphocytic thyroiditis. There were 358 (35%) patients who had central lymph node metastasis. Multivariate analysis showed that younger age (odds ratio = 0.667, P = .013, 95% confidence interval 0.482-0.555), male sex (odds ratio = 0.549, P < .001, 95% confidence interval 0.402-0.751), tumor size >1 cm (odds ratio = 1.454, P = .022, 95% confidence interval 1.053-2.003), extrathyroidal extension (odds ratio = 1.874, P < .001, 95% confidence interval 1.414-2.486), and angiolymphatic invasion (odds ratio = 3.094, P < .001, 95% confidence interval 2.339-4.101) were risk factors for central lymph node metastasis. Angiolymphatic invasion (odds ratio = 11.184, P < .001, 95% confidence interval 3.277-46.199) was identified as the sole independent risk factor for central lymph node metastasis in patients with papillary thyroid carcinoma with coexisting chronic lymphocytic thyroiditis. CONCLUSION: Our data suggest that patients with low to intermediate-risk papillary thyroid carcinoma with coexistent chronic lymphocytic thyroiditis exhibit different clinical features than patients with papillary thyroid carcinoma without chronic lymphocytic thyroiditis. Additionally, the presence of chronic lymphocytic thyroiditis may be considered a potential factor against central lymph node metastasis.
引用
- Heo DB, Won HR, Tae K, et al. Clinical impact of coexistent chronic lymphocytic thyroiditis on central lymph node metastasis in low- to intermediate-risk papillary thyroid carcinoma: The MASTER study. Surgery. 2024. PMID: 38281855. doi:10.1016/j.surg.2023.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。